235 related articles for article (PubMed ID: 34991617)
1. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
[TBL] [Abstract][Full Text] [Related]
2. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
3. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
8. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
9. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
10. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
[TBL] [Abstract][Full Text] [Related]
11. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection.
Zhen S; Qiang R; Lu J; Tuo X; Yang X; Li X
Mol Immunol; 2021 Feb; 130():7-13. PubMed ID: 33340931
[TBL] [Abstract][Full Text] [Related]
13. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
14. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform.
Pan Y; Yang J; Luan X; Liu X; Li X; Yang J; Huang T; Sun L; Wang Y; Lin Y; Song Y
Sci Adv; 2019 Apr; 5(4):eaav7199. PubMed ID: 30949579
[TBL] [Abstract][Full Text] [Related]
17. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
